AbbVie (ABBV) shares snapped eight consecutive sessions of losses as the stock closed up XYZ% at $XYZ. The North ...

Many patients with rheumatic diseases refrain from telling their doctors about all physical and emotional symptoms they’re ...

As the first FRα-targeted ADC approved in the EU, Elahere represents a competitive advantage for AbbVie in the ovarian cancer ...

Last year, pharmaceutical giant AbbVie (NYSE: ABBV) lost patent exclusivity for its biggest cash cow, immunology medicine ...

With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...

AbbVie (ABBV) took a big hit after an adult schizophrenia drug missed its primary endpoint in mid-stage trials. Analysts are ...

AbbVie has rewarded shareholders again with a quarterly dividend. As a Dividend King, it is the epitome of a steady and ...

AbbVie serves a diverse range of clients, primarily in the healthcare sector, including healthcare providers, pharmacies, government health programs, insurance companies, pharmaceutical wholesalers, ...

The third-quarter earnings season came to an end this week for large drugmakers, with AstraZeneca AZN and Bayer BAYRY ...

Which healthcare stock can dividend investors safely buy? Let's consider two excellent options: AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN).

There’s a big ol’ leak in Abbvie’s drug development pipeline. On Monday, the pharma giant announced that two mid-stage trials ...

Skorney believes that the high placebo response in AbbVie’s trials might indicate poor trial ... Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to ...